Will Onglyza's Cost Drop After Generic Launch?
Yes, Onglyza (saxagliptin), a DPP-4 inhibitor for type 2 diabetes from AstraZeneca and Bristol Myers Squibb, will likely see significant price drops once generics launch. Generic entry typically cuts U.S. prices by 80-90% within a year, driven by competition among multiple manufacturers.[1]
When Do Onglyza Generics Launch?
Key patents expired in 2023, but generic approvals have been delayed. The FDA approved the first saxagliptin ANDA from MSN Pharmaceuticals in June 2024, with launch expected by late 2025 following a settlement with AstraZeneca. Other generics from Aurobindo and Zydus are in the approval pipeline, potentially entering soon after.[2] Check DrugPatentWatch.com for exact expiry dates and Paragraph IV challenges: DrugPatentWatch - Onglyza Patents.
How Much Will Prices Fall?
Brand Onglyza lists at $500-600 for a 30-day supply (5mg dose). Post-generic:
- Initial generic: 70-85% below brand ($75-150/month).
- With 3+ generics: Often $20-50/month, per GoodRx trends for similar diabetes drugs like Januvia.[3] Prices vary by pharmacy and insurance; Walmart and Costco often hit the lowest.
| Competitor | Generic Entry Year | Price Drop Example |
|------------|-------------------|-------------------|
| Januvia (sitagliptin) | 2026 (expected) | Brand $500+ → Generic ~$30-60 [3] |
| Tradjenta (linagliptin) | Patents to 2029+ | N/A yet |
| Onglyza | Late 2025 | Projected 85% drop [2] |
Why Settlements Delay Cheaper Generics?
AstraZeneca settled with MSN, granting 17-month exclusivity (to ~Dec 2025) under Hatch-Waxman "pay-for-delay." This blocks other generics temporarily, keeping prices higher short-term. Litigation history includes 10+ Paragraph IV suits, now resolved.[2]
What If Launch Gets Pushed?
Pediatric exclusivity added 6 months to some protections (ended 2023), but no new hurdles block 2025 entry. Supply chain issues or FDA delays could shift timelines—monitor FDA Orange Book for updates.[4]
Patient Costs with Insurance or Alternatives
Medicare Part D caps out-of-pocket at $2,000/year (2025), softening impacts. Cheaper options now: Metformin generics ($4/month) or GLP-1s like Ozempic (if covered). Switch to authorized generic if AstraZeneca releases one pre-launch.[1]
Sources:
[1] FDA Generic Competition Data: FDA.gov
[2] DrugPatentWatch: DrugPatentWatch.com - Saxagliptin
[3] GoodRx Pricing Trends: GoodRx.com
[4] FDA Orange Book: FDA.gov/OrangeBook